Over the past 12‑18 months the Radiation Therapy Test Phantom industry trends have accelerated through a wave of strategic moves. In early 2024, Varian partnered with Standard Imaging to co‑develop an AI‑enhanced end‑to‑end QA platform, leveraging machine‑learning for faster dose verification. Meanwhile, Elekta completed the acquisition of the UK‑based phantom specialist Dosimetrics, expanding its portfolio of patient‑specific dosimetry solutions. Product innovation also surged; Philips unveiled a fully 3‑D‑printed anthropomorphic phantom with embedded sensors that stream real‑time dosimetric data to cloud‑based analytics dashboards. Regulatory momentum followed, as the FDA released revised guidance in July 2024 clarifying compliance pathways for software‑controlled test phantoms, prompting faster market entry. On the demand side, hospitals adopting adaptive radiotherapy reported a 30 % increase in phantom utilization, shifting procurement focus toward modular, reusable designs. Finally, startup PhantomTech secured a $45 million Series B round, earmarked for scaling its modular phantom ecosystem across North America and Europe. The company also announced new manufacturing facilities in Singapore and Ireland, boosting regional supply chain resilience and shortening delivery lead times for European and Asia‑Pacific clients.
